Literature DB >> 28888619

Natural killer cell-mediated immunosurveillance of human cancer.

Karl-Johan Malmberg1, Mattias Carlsten2, Andreas Björklund3, Ebba Sohlberg4, Yenan T Bryceson2, Hans-Gustaf Ljunggren5.   

Abstract

The contribution of natural killer (NK) cells to immunosurveillance of human cancer remains debatable. Here, we discuss advances in several areas of human NK cell research, many of which support the ability of NK cells to prevent cancer development and avoid relapse following adoptive immunotherapy. We describe the molecular basis for NK cell recognition of human tumor cells and provide evidence for NK cell-mediated killing of human primary tumor cells ex vivo. Subsequently, we highlight studies demonstrating the ability of NK cells to migrate to, and reside in, the human tumor microenvironment where selection of tumor escape variants from NK cells can occur. Indirect evidence for NK cell immunosurveillance against human malignancies is provided by the reduced incidence of cancer in individuals with high levels of NK cell cytotoxicity, and the significant clinical responses observed following infusion of human NK cells into cancer patients. Finally, we describe studies showing enhanced tumor progression, or increased cancer incidence, in patients with inherited and acquired defects in cellular cytotoxicity. All these observations have in common that they, either indirectly or directly, suggest a role for NK cells in mediating immunosurveillance against human cancer. This opens up for exciting possibilities with respect to further exploring NK cells in settings of adoptive immunotherapy in human cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; HLA; Immune escape; Immunoediting; Immunosurveillance; Immunotherapy; Induced self; Leukemia; MHC class I; Missing self; NK cell; Natural killer cell; Tumor

Mesh:

Year:  2017        PMID: 28888619     DOI: 10.1016/j.smim.2017.08.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  94 in total

1.  Inducing Fat to Feed a Natural Killer of Malignancy.

Authors:  Benedetta Rambaldi; Rizwan Romee
Journal:  Mol Ther       Date:  2019-04-13       Impact factor: 11.454

Review 2.  [What is established in cell therapies? : Possibilities and limits in immuno-oncology].

Authors:  A Quaiser; U Köhl
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

3.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Authors:  Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

4.  The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.

Authors:  Annalisa Del Prete; Francesca Sozio; Tiziana Schioppa; Andrea Ponzetta; William Vermi; Stefano Calza; Mattia Bugatti; Valentina Salvi; Giovanni Bernardini; Federica Benvenuti; Annunciata Vecchi; Barbara Bottazzi; Alberto Mantovani; Silvano Sozzani
Journal:  Cancer Immunol Res       Date:  2019-09-04       Impact factor: 11.151

Review 5.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

6.  Comment on: Evidence of innate lymphoid cell redundancy in humans.

Authors:  Jordan S Orange; Emily M Mace; Anthony R French; Wayne M Yokoyama; Todd A Fehniger; Megan A Cooper
Journal:  Nat Immunol       Date:  2018-08       Impact factor: 25.606

7.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

8.  Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model.

Authors:  Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yu Li; Quanhong Ma; Vahid Yaghmai; Yuri Velichko; Chunhong Hu; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 9.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

Review 10.  Natural killer cell education in human health and disease.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Curr Opin Immunol       Date:  2018-02-03       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.